Abstract:BACKGROUND Aldosterone has been implicated in a variety of organ fibroses, but its role and mechanism in liver fibrosis remain unclear. METHODS Rat primary hepatic stellate cells (HSCs) were isolated, cultured, and characterized. HSCs were incubated with aldosterone (10(-6) M) for 4 h, 8 h, 12 h, 24 h, and 48 h, after which TGF-β1 (transforming growth factor beta 1) expression was measured by real-time PCR. Rat HSCs were treated with different concentrations of aldosterone (10(-6) M, 10(-7) M, 10(-8) M, and 10(-9) M), and the expressions of PAI-1 (plasminogen activator inhibitor-1) and TGF-β1 were determined by measuring mRNA and protein. HSCs were incubated in groups containing aldosterone (10(-6) M), spironolactone (10(-5) M), both aldosterone and spironolactone, or neither aldosterone nor spironolactone (control), after which mRNA and protein expression of PAI-1 and TGF-β1 were measured. Collagen I expression was detected by immunohistochemical analysis of supernatants of the aldosterone (10(-6) M), TGF-β1, and aldosterone plus TGF-β1 groups. SMAD expression was detected in rat HSC control, HSC plus aldosterone (10(-6) M), HSC plus TGF-β1, and HSC plus aldosterone plus TGF-β1 groups. RESULTS HSCs were incubated with aldosterone for 4 h, 8 h, 12 h, 24 h, and 48 h after which TGF-β1 expression was measured. We found that TGF-β1 expression increased in a time dependent manner and reached a peak at 24 h. The expression of TGF-β1 in groups treated with aldosterone for 4 h, 8 h, 12 h, and 24 h was significantly different from the control group (P < 0.01). No significant difference was seen in TGF-β1 expression between the groups treated with aldosterone for 24 h and 48 h (P > 0.05). Compared with the control group, TGF-β1 expression was significantly increased after incubation with different concentrations of aldosterone (10(-6) M, 10(-7) M, 10(-8) M, and 10(-9) M) (P < 0.01). There were significant differences in the expression of TGF-β1 between 10(-6) M and 10(-7) M aldosterone treatment groups (P < 0.01). Compared with the control group, the expression of PAI-1 was significantly increased after incubation with different concentrations of aldosterone (10(-6) M, 10(-7) M, 10(-8) M, and 10(-9) M) (P < 0.01). PAI-1 expression was increased in the aldosterone, spironolactone, and aldosterone plus spironolactone groups. The expression of PAI-1 was significantly enhanced in the aldosterone and aldosterone plus spironolactone groups compared with the control group (P < 0.01). There was a marked enhancement of collagen I expression in the aldosterone, TGF-β1, and aldosterone plus TGF-β1 groups (P < 0.05). Collagen I expressions in the aldosterone and TGF-β1 groups were significantly different from the aldosterone plus TGF-β1 group (P < 0.01). Compared with the control group, SMAD expression was markedly elevated in the aldosterone, TGF-β1, and aldosterone plus TGF-β1 groups (P < 0.05). The expression of SMAD was significantly increased in the aldosterone plus TGF-β1 group compared with the aldosterone group (P < 0.01). CONCLUSION This study demonstrated that aldosterone promoted HSC activation and the expression of TGF-β1, PAI-1, and collagen in hepatic fibrosis progression and that spironolactone administration partially reversed the effects. The aldosterone promotional effect on hepatic fibrosis was partially mediated by TGF-β1.

Treatment with spironolactone for 24 weeks decreases the level of matrix metalloproteinases and improves cardiac function in patients with chronic heart failure of ischemic etiology

Cardiac remodeling secondary to chronic volume overload is attenuated by a novel MMP9/2 blocking antibody

Spironolactone Improves Myocardial Fibrosis in Spontaneously Hypertensive Rats

The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart ‘OMics’ in AGEing (HOMAGE) randomized clinical trial

Proteomic Analysis of Effects of Spironolactone in Heart Failure With Preserved Ejection Fraction

Spirolactone provides protection from renal fibrosis by inhibiting the endothelial–mesenchymal transition in isoprenaline-induced heart failure in rats

Retrospective study on the short-term efficacy of different doses of Spironolactone in patients with heart failure of ischemic cardiomyopath and the influence of ventricular remodeling markers

Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial

Effect of spironolactone on cardiac remodeling after acute myocardial infarction

Change in the collagen metabolic markers of ischemic cardiomyopathy and its clinical significance

Effects of Spironolactone on the Left Ventricular Remodeling In Renovascular Hypertension Rats

Proteomic profiles of left atrial volume and its influence on response to spironolactone: Findings from the HOMAGE trial and STANISLAS cohort

Effects of Spironolactone,Losartan and Combination Therapy on Myocardial Angiogenesis during the Early State of Post Myocardial Infarction in Rats

Effect of Atorvastatin on Non-Ischemic Heart Failure and Matrix Metalloproteinase-2 and 9 in Rats

Effect of Aldosterone and Its Antagonist on the Expression of PAI-1 and TGF-β1 in Rat Hepatic Stellate Cells.

Small doses of spironolactone decrease the levels of BNP and hs-CRP of patients with acute myocardial infraction

Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone

Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof‐of‐concept, randomised, precision‐medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial

Impact of Mineralocorticoid Receptor Antagonists on Changes in Cardiac Structure and Function of Left Ventricular Dysfunction

Imbalance of Matrix Metalloproteinases/Tissue Inhibitor of Metalloproteinase-1 and Loss of Fibronectin Expression in Patients with Congestive Heart Failure